Summary
Aurobindo Pharma Ltd (Aurobindo Pharma) is a pharmaceutical company that develops, manufactures and exports generic pharmaceuticals and active pharmaceutical ingredients. The company offers active pharma ingredients, formulations, antibiotics, anti-retrovirals, anti- allergics, HIVs, peptides, nutraceutical and aurozymes. It offers contract research and manufacturing services across all the clinical stages of drug lifecycle. Aurobindo Pharma conducts research and development in the areas of product identification, literature evaluation, API process development, formulation development, pilot BA / BE, exhibiting batches for dossier submission, stability studies for global requirements, and dossier submission. The company has presence in China, South Africa, Australia, Germany, Japan, the US, the UK, and others. Aurobindo pharma is headquartered in Hyderabad, Telangana, India.
Aurobindo Pharma Ltd (AUROPHARMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aurobindo Pharma Acquires Four Biosimilar Products from TL Biopharma 13
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 13
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 14
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For US$40.8 Million 15
Private Equity 17
Aurobindo Pharma May Raise USD200 Million in Private Equity Financing 17
KKR May Acquire 4% Stake in Aurobindo Pharma for up to USD299 Million 18
Partnerships 19
Aurobindo Pharma Forms Joint Venture with Tergene Biotech 19
Celon Labs Forms Joint Venture with Aurobindo Pharma 19
Aurobindo Pharma Forms Joint Venture With DIODE 20
Licensing Agreements 21
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 21
Aurobindo Pharma Extends its Licensing Agreement with Medicines Patent Pool 22
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool 22
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool for Lopinavir/Ritonavir 23
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 24
Equity Offering 25
Aurobindo Pharma Plans to Raise USD300 Million in Private Placement of Shares 25
Aurobindo Pharma Receives Board Approval for Private Placement of Shares for up to USD350 Million 25
Debt Offering 27
Aurobindo Pharma May Raise USD300 Million in Public Offering of Bonds 27
Asset Transactions 27
Aurobindo Pharma Sells Manufacturing Facility In Tamilnadu 27
Acquisition 28
Aurobindo Pharma to Acquire Generis Farmaceutica from Magnum Capital Partners for USD142.8 Million 28
Eris Pharma Acquires Aurobindo Pharma Australia from Aurobindo Pharma 29
Aurobindo Pharma Acquires Natrol for USD132.5 Million 30
Aurobindo Pharma Acquires Hyacinths Pharma for up to USD3 Million 31
Aurobindo Pharma Acquires Remaining 25% Stake in Silicon Life Sciences from ABS Mercantiles 32
Aurobindo Pharma To Acquire Branded Formulations Marketing Company 32
China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma 33
Aurbindo Pharma Sells 50% Stake In Cephazone Pharma, Maker Of Cephalosporin Products 34
Aurobindo Pharma Ltd - Key Competitors 36
Key Employees 37
Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List of Tables
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aurobindo Pharma Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Aurobindo Pharma Acquires Four Biosimilar Products from TL Biopharma 13
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 13
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 14
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For US$40.8 Million 15
Aurobindo Pharma May Raise USD200 Million in Private Equity Financing 17
KKR May Acquire 4% Stake in Aurobindo Pharma for up to USD299 Million 18
Aurobindo Pharma Forms Joint Venture with Tergene Biotech 19
Celon Labs Forms Joint Venture with Aurobindo Pharma 19
Aurobindo Pharma Forms Joint Venture With DIODE 20
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 21
Aurobindo Pharma Extends its Licensing Agreement with Medicines Patent Pool 22
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool 22
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool for Lopinavir/Ritonavir 23
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 24
Aurobindo Pharma Plans to Raise USD300 Million in Private Placement of Shares 25
Aurobindo Pharma Receives Board Approval for Private Placement of Shares for up to USD350 Million 25
Aurobindo Pharma May Raise USD300 Million in Public Offering of Bonds 27
Aurobindo Pharma Sells Manufacturing Facility In Tamilnadu 27
Aurobindo Pharma to Acquire Generis Farmaceutica from Magnum Capital Partners for USD142.8 Million 28
Eris Pharma Acquires Aurobindo Pharma Australia from Aurobindo Pharma 29
Aurobindo Pharma Acquires Natrol for USD132.5 Million 30
Aurobindo Pharma Acquires Hyacinths Pharma for up to USD3 Million 31
Aurobindo Pharma Acquires Remaining 25% Stake in Silicon Life Sciences from ABS Mercantiles 32
Aurobindo Pharma To Acquire Branded Formulations Marketing Company 32
China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma 33
Aurbindo Pharma Sells 50% Stake In Cephazone Pharma, Maker Of Cephalosporin Products 34
Aurobindo Pharma Ltd, Key Competitors 36
Aurobindo Pharma Ltd, Key Employees 37
Aurobindo Pharma Ltd, Other Locations 38
Aurobindo Pharma Ltd, Subsidiaries 38
List of Figures
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
